Skip to main content
. 2018 Jul 24;9(5):962–974. doi: 10.1002/jcsm.12321

Figure 7.

Figure 7

Knockdown of Atrolnc‐1 improves muscle atrophy in mice with chronic kidney disease (CKD). (A) Timeline of experimental design. Arrow denotes time point of AAV1‐shArolnc‐1 injection and subtotal nephrectomy. (B) Tibialis anterior (TA) muscles of normal C57BL/6 mice and CKD mice were transfected with AAV1‐shAtrolnc‐1, while AAV1‐CTL was transfected as control. The Atrolnc‐1 mRNA level was significantly reduced after the knockdown of Atrolnc‐1 (mean ± SEM; n = 9). (C) The weight of TA muscles (normalized by tibia length) was significantly lower in CKD mice transfected with AAV1‐CTL, compared with muscles transfected by AAV1‐shAtrolnc‐1 (mean ± SEM; n = 9). (D) After 3 weeks of transfection with AAV1‐shAtrolnc‐1, the cross‐sectional area of cryosections (6 μm) from TA muscle was shown by immunostaining with anti‐dystrophin antibody. Scale bars: 50 μm. The distribution of myofiber cross‐sectional area was shifted rightward in TA muscles transfected with AAV1‐shAtrolnc‐1 compared with AAV1‐CTL (n = 5). (E) The decrease of MuRF‐1 mRNA in TA muscles with Atrolnc‐1 knockdown was confirmed by RT‐qPCR (mean ± SEM; n = 5).